Monday , October 23 2017
Home / Letter From The Editor / Letter from the Editor: JP Morgan Conference, Eli Lilly-Boehringer Ingelheim News and More on Accidental Insulin Injection

Letter from the Editor: JP Morgan Conference, Eli Lilly-Boehringer Ingelheim News and More on Accidental Insulin Injection

Last week, many companies in the diabetes world were in San Francisco to present at the J.P. Morgan Healthcare Conference. Our own president, Andrew Young, was in attendance to see and hear what was going on, and to sum it up, 2011 does not look like a breakthrough year for novel, new, marketable diabetes therapies. Although each one of the 336 companies that presented had a whole lot to say about their pipelines and market share the fact is that diabetes drugs are going off patent at a much greater rate than new ones are getting approved.

One of the biggest news items was the announcement by Eli Lilly and Boehringer Ingelheim of a new alliance to develop and bring new diabetes treatments to market. In their joint press release they announce a global agreement to develop and commercialize a portfolio of diabetes compounds currently in mid- and late-stage development. Included are Boehringer Ingelheim’s two oral diabetes agents — linagliptin (a DPP-IV-inhibitor) and BI10773 (an sglt-2-inhibitor) as well as Lilly’s two basal insulin analogues — LY2605541 and LY2963016 — and the option to co-develop and co-commercialize Lilly’s anti-TGF-beta monoclonal antibody. If you want to know more we have the whole press release for you.

Last week in our Diabetes Clinical Mastery Series newsletter our Diabetes Disaster Averted #15: Handling Accidental Insulin Injection, dealt with the accidental injection of insulin intended for a dog into an older patient’s hand. There were many of you who wanted to know more about the use of insulin in pets so our intern, Janine Manning, PharmD Candidate 2011, Lake Erie College of Osteopathic Medicine, School of Pharmacy, prepared a short paper on the use of insulin in pets. Click here to read Pharmacotherapy Options in the Treatment of Feline and Canine Diabetes.

***

Many of you have helped patients avert diabetes disasters and we can all learn from them. (See our Safety and Error Prevention Topic page for a complete list.) If you have a “disaster averted” then send it in and if we use it in our Diabetes Clinical Mastery Series you will receive a Visa Gift Card worth $50.00. Congratulations to our readers who have been sent gift cards for their contributions! Click here to let us know the details. (You can use your name or remain anonymous if you prefer.)

Announcements:

TCOYD Conference and Health Fair, Santa Rosa, California, Feb 12, 2011

The TCOYD team starts their regular conference and health fair schedule this year in Santa Rosa, with Special Guest, Billy Mills, Olympic Gold Medalist. Features and Events include: top physicians, diabetes educators, foot specialists; state-of-the-art technologies and advances in diabetes care; afternoon workshops; and physical activities for everyone.

dLife.com: January 16, 7PM ET on CNBC

Topics: The dLife season premiere brings you the harrowing story of Ernest Sterzer, a type 1 teenager who survived the unthinkable in Nazi Germany. Also, a special tribute to the late, great sports legend, Ron Santo. Sundays on CNBC at 7 PM ET, 6 PM CT, and 4 PM PT. Catch up on dLife.com.

Please answer this week’s poll (in the right-hand column): Is it appropriate for the government to pay for end-of-life counseling?

*****************************
We can make a difference!
*****************************

Check out this week’s “Test Your Diabetes Knowledge” question!

Dave Joffe, Editor-in-chief